Resources Repository
-
ArticlePublication 2023Valuing Mortality Risk: Per Life, Life Year, or QALY?
It is important to consider age and other relevant factors when assessing the value associated …
It is important to consider age and other relevant factors when assessing the value associated with reducing risks to ensure a comprehensive and accurate understanding of its impact. In a recent paper, it is explained that the value of risk reduction, whether it is a temporary or persistent reduction, can be defined using the "value per statistical life" (VSL), "value per statistical life year" (VSLY), or "value per quality-adjusted life year" (VQALY).
Preferences/Values | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Risk Analysis -
ArticlePublication 2017Estimating the Fitness Cost and Benefit of Cefixime Resistance in Neisseria Gonorrhoeae
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more …
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more than half of annual infections occur in men who have sex with men (MSM). As the bacterium has developed resistance to each first-line antibiotic in turn, an improved understanding is needed of fitness benefits and costs of antibiotic resistance to inform control policy and planning. The authors developed a stochastic compartmental model representing the natural history and transmission of cefixime-sensitive…
Risk Analysis | Decision Analysis | Dynamic Transmission | Infectious Diseases | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Science/Technology | Global -
ReportPublication 2017Economic Value of Informal Mental Health Caring
Caregivers, family and friends play a significant role in supporting people with mental illness, and …
Caregivers, family and friends play a significant role in supporting people with mental illness, and it has long been recognized that informal carers constitute a significant ‘hidden’ workforce in Australia. Faced as Australia is with an ageing population and burgeoning chronic disease, data on the contribution that carers make and the consequent savings to governments and other ‘payers’ need to be articulated. This report attempts to put a ‘value’ on informal caring for those with mental illness.…
Preferences/Values | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Chronic Disease/Risk | Mental Health | Health Systems | Economics/Finance | Health/Medicine | Oceania -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Preferences/Values | Technology Assessment | Cost-Effectiveness Analysis | Health Outcomes | Mathematical Models | Health Systems | Health/Medicine | Science/Technology | North America | Europe -
ArticlePublication 2015Broader Economic Impact of Vaccination: Reviewing and Appraising the Strength of Evidence
Economic evaluations of public health programs such as immunization often consider only direct health benefits and …
Economic evaluations of public health programs such as immunization often consider only direct health benefits and medical cost savings. Evidence linking immunization to important benefits in indicators such as childhood development, household behavior, and other macro-economic data are unclear. A conceptual framework of the pathways between immunization and these broader economic benefits was developed through expert consultation. The authors obtained articles from previous reviews, snowballing, and expert consultation, and associated them with one of the pathways and assessed them using modified Grading…
Preferences/Values | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Infectious Diseases | Social Determinants | Economics/Finance | Education/Labor | Health/Medicine -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Preferences/Values | Technology Assessment | Cost-Effectiveness Analysis | Health Outcomes | Evidence Synthesis | Chronic Disease/Risk | Mental Health | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology | North America -
GuidelinesPublication 2014EPA Guidelines for Preparing Economic Analyses
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for …
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for assessing the impacts of environmental regulations and policies that has been extensively peer-reviewed and is widely-applied both within and outside of the agency. The Guidelines discuss: (1) statutory and executive order requirements for conducting economic analyses; (2) identifying the need for policy action; (3) regulatory and non-regulatory approaches to pollution control; (4) baseline definition; (5) discounting future benefits and costs;…
Preferences/Values | Benefit-Cost Analysis | Decision Analysis | Priority Setting/Ethics | Environmental Health | Policy/Regulation | Climate/Environment | Government/Law | North America | Critical Thinking/Analysis -
ArticlePublication 2007Decision Analysis: A Personal Account of How It Got Started and Evolved
In this chapter, Howard Raiffa discusses the evolution of decision analysis and his personal involvement …
In this chapter, Howard Raiffa discusses the evolution of decision analysis and his personal involvement in its development. He describes the early days of Operations Research (OR) in the late 1940s with its approach to complex, strategic decision making. After reading John von Neumann and Oskar Morgenstern’s Theory of Games and Economic Behavior (1947) and Abraham Wald’s two books (1947, 1950), he became involved in statistical decision theory. A few years later, after reading Leonard…
Preferences/Values | Operations Research | Decision Analysis | Decision Theory | Probability/Bayes | Business/Industry | Economics/Finance | Energy/Engineering | Health/Medicine -
ArticlePublication 2023Alternative Measure of Health for Value Assessment: Equal Value Life-Year
This study examines the equal value life-year (evLY) as an alternative or complementary measure to …
This study examines the equal value life-year (evLY) as an alternative or complementary measure to the quality-adjusted life-year (QALY) in cost-effectiveness analyses. The QALY is criticized for undervaluing treatments that extend the life of individuals with chronic disabilities. The evLY addresses this by assigning equal value to life-years, regardless of health status. Methods included presenting the conceptual rationale for the evLY, explaining its estimation, and comparing results from evLY-based analyses to QALY-based analyses. The study…
Preferences/Values | Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine